One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin.
Publication/Presentation Date
9-1-2010
Abstract
While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.
Volume
24
Issue
3
First Page
767
Last Page
769
ISSN
1791-2431
Published In/Presented At
Brown, D. B., Gonsalves, C. F., Yeo, C. J., Witkiewicz, A. K., & Carr, B. I. (2010). One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin. Oncology reports, 24(3), 767–769. https://doi.org/10.3892/or_00000919
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
20664985
Department(s)
Administration and Leadership
Document Type
Article